Factors associated with mortality among hospitalized patients with COVID-19 disease treated with convalescent plasma

Vista sencilla de ítem
dc.citation.titlemBio
dc.citation.volume1-9
dc.contributor.orcidhttp://orcid.org/0000-0002-8472-7965
dc.creatorPerichon, Armando M.
dc.creatorAcosta, Andrea
dc.creatorDi Tullio, Liliana
dc.creatorMunuce, María José
dc.creatorPezzotto, Stella
dc.creatorBottasso, Oscar
dc.date.accessioned2024-02-09T18:46:11Z
dc.date.available2024-02-09T18:46:11Z
dc.date.issued2023-11-08
dc.description.abstractThe use of convalescent plasma (CP) for hospitalized patients with SARSCoV-2 infection might be a useful option in certain settings. Soon after the outbreak of COVID-19, the National Ministry of Health of Argentina recommended the use of CP transfusion for hospitalized patients with COVID-19 disease. Between 1 June and 3 October 2020, 480 patients, excluding those on invasive mechanical ventilation (IMV), received at least one CP infusion in the province of Santa Fe. We aimed to find factors associated with mortality among this cohort of patients. The median age was 60 years (interquartile range: 49–69 years) and 320 (66.7%) were males. Most of these patients (93.75%) received a single CP infusion, 82.1% and 95.6% before day 4 and day 7 of hospitalization, respectively. Anti-SARS-CoV-2 titers were determined in the CP units administered using Elecsys Anti-SARS-CoV-2 S assay. At 28 days of follow-up, 250 patients were discharged (52.1%), 131 (27.3%) remained hospitalized without and 16 (3.3%) with oxygen requirement, 27 (5.6%) were on IMV, and 56 (11.7%) had died. In the multivariate logistic regression analysis, the factors significantly associated with 28-day mortality were (i) requirement of IMV, (ii) the administration of CP after the third day of hospitalization, (iii) age, and (iv) number of comorbidities. The qualitative and quantitative analyses of antibodies against SARS-CoV-2 in the infused CP were not associated with mortality. Our findings may imply a seemingly favorable effect of CP administration among patients with severe COVID-19 disease when infused sooner after hospitalization.
dc.description.filFil: Perichon, Armando M. Ministerio de Salud. Centro Único de Donación, Ablación e Implante de Órganos; Argentina.
dc.description.filFil: Acosta, Andrea. Ministerio de Salud. Centro Regional de Hemoterapia Sur; Argentina.
dc.description.filFil: Di Tullio, Liliana. Ministerio de Salud. Centro Regional de Hemoterapia Sur; Argentina.
dc.description.filFil: Munuce, María José. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Laboratorio de Medicina Reproductiva. Área Bioquímica Clínicas; Argentina.
dc.description.filFil: Pezzotto, Stella. Universidad Nacional de Rosario. Instituto de Inmunología Clínica y Experimental de Rosario. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina.
dc.description.filFil: Pezzotto, Stella. Universidad Nacional de Rosario, Rosario. Consejo de Investigaciones; Argentina.
dc.description.filFil: Bottasso, Oscar. Universidad Nacional de Rosario. Instituto de Inmunología Clínica y Experimental de Rosario. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina.
dc.description.filFil: Bottasso, Oscar. Universidad Nacional de Rosario, Rosario. Consejo de Investigaciones; Argentina.
dc.description.filFil: Nannini, Esteban C. Universidad Nacional de Rosario. Instituto de Inmunología Clínica y Experimental de Rosario. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina.
dc.description.filFil: Nannini, Esteban C. Sanatorio Británico. Servicio de Infectología; Argentina.
dc.identifier.issn2161-2129
dc.identifier.urihttps://hdl.handle.net/2133/26682
dc.language.isoen
dc.publisherAmerican Society for Microbiology
dc.relation.publisherversionhttps://doi.org/10.1128/mbio.02565-23
dc.relation.publisherversionhttps://journals.asm.org/doi/10.1128/mbio.02565-23
dc.rightsopenAccess
dc.rights.holderPerichon, Armando M.
dc.rights.holderAcosta, Andrea
dc.rights.holderDi Tullio, Liliana
dc.rights.holderMunuce, María José
dc.rights.holderPezzotto, Stella
dc.rights.holderBottasso, Oscar
dc.rights.holderNannini, Esteban C.
dc.rights.holderUniversidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas
dc.rights.textAttribution 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectSARS-CoV-2
dc.subjectCOVID-19
dc.subjectPneumonia
dc.subjectConvalescent plasma
dc.subjectTransfusion
dc.subjectImmunotherapy
dc.titleFactors associated with mortality among hospitalized patients with COVID-19 disease treated with convalescent plasma
dc.typearticulo
dc.type.versionpublishedVersion

Archivos

Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
Factors associated with mortality among hospitalized patients with COVID-19 disease treated with convalescent plasma.pdf
Tamaño:
217.67 KB
Formato:
Adobe Portable Document Format
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
Nombre:
license.txt
Tamaño:
3.87 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

(FBIOyF) Departamento de Microbiología - Artículos
(FBIOyF) Departamento de Bioquímica Clínica - Artículos
(FBIOyF) Departamento de Química Física - Artículo de Revista
(FBIOyF) Laboratorio de Medicina Reproductiva (LMR) - Artículo de Revista